Effect of treatment with GnRH agonists on new markers of bone metabolism
This study found that urinary N-telopeptides increased by 44% and bone-specific alkaline phosphatase increased by 40% after 3 months of GnRH agonist treatment in women, indicating increased bone resorption and formation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (11)
- Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin via openalex
- Excretion of urinary N-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss via openalex
- Gonadotropin releasing hormone agonist therapy and its effect on bone mass via openalex
- Treatment of Endometriosis with the Luteinizing Hormone-Releasing Hormone Agonist Nafarelin. Effect on Bone Turnover and Bone Mass via openalex
- Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy via openalex
- W2062982521 via openalex
- W2078249213 via openalex
- W2115941653 via openalex
- W2027858461 via openalex
- W2013079995 via openalex
- W2059516397 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-10-08T20:58:50.057178+00:00
- unpaywall
- last seen: 2026-10-15T06:24:24.424788+00:00